| dc.contributor.author | Wangensteen, Rosemary | |
| dc.contributor.author | Gómez Guzmán, Manuel | |
| dc.contributor.author | Banegas, Inmaculada | |
| dc.contributor.author | Rodríguez-Gómez, Isabel | |
| dc.contributor.author | Jiménez, Rosario | |
| dc.contributor.author | Duarte, Juan | |
| dc.contributor.author | García-Estañ, Joaquín | |
| dc.contributor.author | Vargas, Félix | |
| dc.date.accessioned | 2024-09-16T08:52:17Z | |
| dc.date.available | 2024-09-16T08:52:17Z | |
| dc.date.issued | 2022-05-25 | |
| dc.identifier.citation | Wangensteen, R. et. al. Biomedicines 2022, 10, 1230. [https://doi.org/10.3390/biomedicines10061230] | es_ES |
| dc.identifier.uri | https://hdl.handle.net/10481/94466 | |
| dc.description.abstract | This study investigated the vasoactive effects of des-aspartate-angiotensin-I (DAA-I) in
male Wistar rats on whole body vascular bed, isolated perfused kidneys, and aortic rings. Dose–
response curves to DAA-I were compared with those to angiotensin II (Ang II). The Ang II-type-1
(AT1) receptor blocker, losartan, was used to evaluate the role of AT1 receptors in the responses
to DAA-I. Studies were also conducted of the responsiveness in aortic rings after endothelium
removal, nitric oxide synthase inhibition, or AT2 receptor blockade. DAA-I induced a dose-related
systemic pressor response that was shifted to the right compared with Ang II. Losartan markedly
attenuated the responsiveness to DAA-I. DAA-I showed a similar pattern in renal vasculature
and aortic rings. In aortic rings, removal of endothelium and nitric oxide inhibition increased the
sensitivity and maximal response to DAA-I and Ang II. AT2 receptor blockade did not significantly
affect the responsiveness to DAA-I. According to these findings, DAA-I increases the systemic
blood pressure and vascular tone in conductance and resistance vessels via AT1 receptor activation.
This vasoconstrictor effect of DAA-I participates in the homeostatic control of arterial pressure,
which can also contribute to the pathogenesis of hypertension. DAA-I may therefore be a potential
therapeutic target in cardiovascular disease. | es_ES |
| dc.description.sponsorship | Carlos III Health Institute of Spain grant number
PI18/01715 and the Cooperative Research Network RICORS2040, RD21/0005/0015 “FEDER a way
to make Europe” | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | MDPI | es_ES |
| dc.rights | Atribución 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject | renin-angiotensin system | es_ES |
| dc.subject | des-aspartate-angiotensin I | es_ES |
| dc.subject | vascular reactivity | es_ES |
| dc.title | Vasoconstrictor and Pressor Effects of Des-Aspartate-Angiotensin I in Rat | es_ES |
| dc.type | journal article | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.identifier.doi | 10.3390/biomedicines10061230 | |
| dc.type.hasVersion | VoR | es_ES |